FAP and metastatic neoplasm: However, if the dominant variable regarding the time from diagnosis to development of metastatic disease is excluded from the model, FAP positive immunostaining of the primary tumor (p = 0.0608) and initial metastatic location in lymph nodes (p = 0.139) present as determinant of prognosis in patients with mCCRCC (Table 4).